Loading…
Loading…
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the most recent trading session, McKesson (MCK) closed at $967.02, indicating a -2.6% shift from the previous trading day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson Corp. stands out as an asset-heavy distributor poised to benefit from AI-driven prescription automation and expedited FDA rare-disease drug approvals. MCK's specialty and oncology segment, with 41% YoY profit growth and superior margins, insulates it from AI disintermediation risks affecting vertically integrated telehealth peers. Despite materially faster EPS growth (24% forward GAAP), MCK trades at only a modest premium (forward P/E 25.75x), with a PEG ratio of 0.55x, suggesting undervaluation.
Carnegie Investment Counsel raised its position in McKesson Corporation (NYSE: MCK) by 56.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,242 shares of the company's stock after acquiring an additional 1,525 shares during the quarter. Carnegie Investment Counsel's holdings in McKesson
The latest trading day saw McKesson (MCK) settling at $1, representing a -1.42% change from its previous close.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufact.